US Edition
Reyobiq Trial for High-Grade Pediatric Glioma Approved by FDA
5 Articles
5 Articles
The new treatment, which combines stem cells with a virus that selectively attacks malignant cells, has made four out of six patients survive more than a year after other therapies failed.A girl with advanced cancer who received CAR-T therapy 18 years ago is still without a trace of disease. These are “hoping” results. This new clinical trial described the president of the CRIS Cancer Foundation, Lola Manterola. The study, which focuses on the t…
Reyobiq trial for high-grade pediatric glioma approved by FDA
Reyobiq (Rhenium Re186 Obisbemeda), an experimental radiation therapy being developed by Plus Therapeutics, has been cleared by the U.S. Food and Drug Administration (FDA) to begin clinical trials that will test the treatment in children with certain aggressive gliomas. This decision follows positive results from the first part of a Phase 1/2a trial (NCT01906385), called ReSPECT-GBM, in adults with recurrent glioma. A $3 million grant from the U…
laprovincia.es
informacion.esAn innovative clinical trial, with an advanced therapy drug for relapsed meduloblastoma -one of the most common malignant brain tumors in children and adolescents-, gives hope to children with this terrible disease. The results of the trial, funded by CRIS Against Cancer, were presented this Thursday at the Madrid Children's Children's University Hospital.
The Children's Hospital Niño Jesús presented "very promising" results on Thursday in an innovative clinical trial based on advanced therapy called AloCeyvir, designed to treat childhood meduloblastoma, a frequent and aggressive malignant brain tumor in children. This study, funded by the Cris Anti-Cancer Foundation, involved six patients — children, adolescents and young adults between 5 and 18 years of age — diagnosed with progression or relaps…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium
